My Stocks Explore Events Please signup to use this feature
Please signup to use this feature
Please signup to use this feature
Please signup to use this feature
Live today
{{event.ticker}} @{{event.event_utc_datetime | date:'h:mm a'}}
{{market.market_short_name}} {{market.last_price | number : 2}}

Want to join the conversation?

$RCL {{ '2016-08-02T14:37:06+0000' | timeago}} • Webcast

$RCL said that in China the company is pleased with the way its cruises have been received by the consumers. On the current booking trends, the company said it is over 93% booked for the year with book load factor and APD in a strong position. $RCL's China sailings, which represent 9% of its capacity, continues to generate above avg. yields.

User Melwyn Jones {{ '2016-10-28T17:16:30+0000' | timeago}}

$CVX posts first profit in a year. Right time to get some shares? My question is, will it sustain this turnaround?

User Josh Allan {{ '2016-10-27T15:39:01+0000' | timeago}}

Jeff Bezos, my inspiration next to Steve Jobs is going to review the Everything Store $AMZN's financial results today after hours. As an investor/user, I like Amazon Prime and it's success over several parts of the world. What's your take on Amazon?

User RC xNair {{ '2016-10-27T13:31:32+0000' | timeago}}

Of all the Wall St firms out there, Goldman Sachs $GS is the most revered for the way they're run - hiring the best, highly competitive, a closely-knit peer group and making tons of profits for the shareholders. An interesting interview of its CEO Llyod Blankfein by Carlyle groups chief David Rubenstein

User Ramesh Raju {{ '2016-10-27T10:38:07+0000' | timeago}}

Deutsche Bank posts Q3 net profit of 278 million euros.

User Vishnu Beri {{ '2016-10-27T01:52:28+0000' | timeago}}

Great results from $TSLA, however the question remains if Tesla can continue to scale up to produce the cars in the quantity it promises. Model 3 numbers need to be in multiples of what they are producing right now. Wish them the best, will keep an eye as I am still not convinced that they can scale easily.

$ALXN {{ '2016-10-28T18:05:15+0000' | timeago}} • Webcast

$ALXN continues to build and strengthen global patent position for both Soliris and ALXN1210. In 3Q16, new U.S. patent was issued for treating kidney affecting disease, atypical hemolytic-uremic syndrome (aHUS), with Soliris that is valid till 2032. $ALXN sees additional patents relating to Soliris over next 12-18 months.

$WY {{ '2016-10-28T18:03:01+0000' | timeago}} • Webcast

$WY has $1.7Bil drawn on the term loan. As it starts closing on the Cellulose Fibers transaction, the company will start paying that down. The company expects this to be paid down hopefully by year-end 2016 or soon around that time.

$WY {{ '2016-10-28T18:00:37+0000' | timeago}} • Webcast

In 2017, $WY will continue to benefit from its cost and operational synergies, continued OpEx improvements and stronger housing markets. The company will be working closely with its Board to determine the right level of dividend going forward.

$AIV {{ '2016-10-28T17:58:04+0000' | timeago}} • Webcast

On Indigo, $AIV said the property is right on track with the initial underwriting. The company would look at a yield there that would be kind of high 4s, low 5s as it stabilizes in the next couple of years. At the time of announcement of acquisition, $AIV expected a stabilized NOI yield of 4.9% and the company is on track to hit that number.

$ALXN {{ '2016-10-28T17:56:17+0000' | timeago}} • Webcast

As providing Strensiq to more patients in the U.S. and extending global launch next year, $ALXN will continue to leverage its expertise in ultra-rare diseases to reach more patients with Hypophosphatasia (HPP), a disease that can damage bones and organs. $ALXN sees Strensiq to continue to be strong additional driver of growth in 2017 and beyond.